Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen by Marc Potenza, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Emalex Biosciences Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.

Research Team

Jon Grant, MD

Principal Investigator

Univ. of Minnesota

Donald Black, MD

Principal Investigator

Iowa University

Timothy Fong, MD

Principal Investigator

University of California, Los Angeles

Marc Potenza, MD

Principal Investigator

Yale University

Eligibility Criteria

Inclusion Criteria

Subject must be diagnosed with Pathological Gambling according to DSMIV criteria

Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening

Subject must have gambling urges of at least moderate intensity

Treatment Details

Interventions

• Ecopipam (Dopamine D1 Receptor Antagonist)

Participant Groups

Group I: Ecopipam Experimental Treatment 1 Intervention

Ecopipam is a selective antagonist of one the classes of dopamine receptor.

Group II: Placebo Placebo Group 1 Intervention

Placebo given first week of the study.

Who Is Running the Clinical Trial?

Emalex Biosciences Inc.

Lead Sponsor

Trials

16

Recruited

1,000+

Psyadon Pharma

Industry Sponsor

Trials

7

Recruited

150+